WHAT IS GENERALIZED MYASTHENIA GRAVIS (gMG)?

Gummedy hysterinid gMG (gMG) is a non-sustained disorder that is led by loss of muscle function and severe in clinical categories.

85% of people with gMG are AChR antibodies. AChR antibodies (anti-AChR) are used to bind to signal receptors at the neuromuscular junction (NMJ). This binding activates the complement system, causing the immune system to attack muscles. This leads to inflammation and destruction of healthy cells. The complement system play an essential role in the body’s defense against infections.

WHAT ROLE DOES COMPLEMENT INHIBITION PLAY IN TREATING gMG?

When the system is thrown out of balance due to the development of certain antibodies, it triggers a dangerous, uncontrolled cascade of reactions known as inflammation and the destruction of healthy cells.

When the system is thrown out of balance due to the development of certain antibodies, it triggers a dangerous, uncontrolled cascade of reactions known as inflammation and the destruction of healthy cells.

WHAT TREATMENT APPROACH IS BEING STUDIED BY ALEXION?

In addition to our continued development of therapies that are approved for adults with gMG, Alexion is committed to advancing research and other clinical trial programs in the disease.

References: